Finally, the fourth hit (third step) involves a tumour-specific pathogenic variant of the NF2 gene located in cis to the SMARCB1 germline PV that leads to biallelic NF2 inactivation driving schwannoma development (Fig. 4A). This evidence concerns the gene NF2 and schwannoma.